drugset / Trial / NCT04700436
Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia
Phase 4
Completed
146 enrolled
Seoul National University Hospital
Gangnam Severance Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare and evaluate the effects of LDL-C and Triglyceride (TG) control on the first dose Ezetimibe/Statin (Rosuvastatin 5 mg/Ezetimibe 10 mg) combination therapy compared to the average dose Statin (Rosuvastatin 10 mg) monotherapy in patients with Type 2 diabetes with hypertriglyceridemia (TG \> 200 mg/dL).
Timeline
- Start
- 2020-01-03
- Primary completion
- 2021-05-28
- Completion
- 2024-02-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ezetimibe | Unknown | 10 mg | — |
| Comparator | Rosuvastatin | Small molecule | 5 mg | — |
| Comparator | Rosuvastatin | Small molecule | 10 mg | — |